Home › NDC Lookup › RxCUI directory › RxCUI 2699831

Imatinib 80 MG/ML Oral Solution — RxCUI 2699831

RxNorm drug concept · Semantic clinical drug
RxCUI 2699831 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2699831
Official nameImatinib 80 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asimatinib 80 MG (equivalent to 95.57 MG imatinib mesylate) per 1 ML Oral Solution
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Imatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Imatinib targets specific proteins that are driving your cancer cells to grow out of control. In leukemias like CML, it blocks a faulty protein called BCR-ABL that results from a g...
  • What exactly is imatinib treating in my body?
  • Yes — always take imatinib with a meal and a large glass of water. Taking it on an empty stomach increases the chance of nausea and stomach irritation. If you're taking the tablet...
  • Does it matter when I take it or whether I eat first?
📖 Read our full Imatinib guide →

🕸️ Concept Web — How Imatinib 80 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Imatinib 80 MG/ML Oral Solution RxCUI 2699831

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Imatinib 282388
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Imkeldi 2699832
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Imatinib Oral Solution 2699830
    • Imatinib Oral Liquid Product 2699829
    • Imatinib Oral Product 1160679
    • Imatinib Oral Solution [Imkeldi] 2699836
    • Imkeldi Oral Liquid Product 2699835
    • Imkeldi Oral Product 2699834
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Imatinib 80 MG/ML SCDC · 2699828
  • Imatinib Oral Solution SCDF · 2699830
  • Imatinib Oral Liquid Product SCDG · 2699829
  • Imatinib Oral Product SCDG · 1160679

Brand-Name Concepts

  • Imatinib 80 MG/ML Oral Solution [Imkeldi] SBD · 2699837
  • Imatinib 80 MG/ML [Imkeldi] SBDC · 2699833
  • Imatinib Oral Solution [Imkeldi] SBDF · 2699836
  • Imkeldi Oral Liquid Product SBDG · 2699835
  • Imkeldi Oral Product SBDG · 2699834
  • Imkeldi BN · 2699832

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2699831 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
81927-0201-01 140 mL in 1 BOTTLE (81927-201-01) IMKELDI Shorla Oncology Inc., 2024-12-19
Observed labelers: Shorla Oncology Inc., (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.